Journal of Pharmacogenomics & Pharmacoproteomics

Usama A Arafa

Publications

• Research Article
  Interleukin-28B Polymorphism is a Pharmacogenetic Predictor during Sofosbuvir Plus Pegylated Interferon and Ribavirin Therapy for Chronic Hepatitis C Egyptian Patients
  Author(s): Hosni Dh Abd EL-Raheem, Medhat H Hashem, Alaa A Hemeida, Mohamed E Ebeed, Usama A Arafa, and Laila M Yousef.Hosni Dh Abd EL-Raheem, Medhat H Hashem, Alaa A Hemeida, Mohamed E Ebeed, Usama A Arafa, and Laila M Yousef.
  
  Background and Aim: Interleukin-28B (IL-28B) polymorphism is a predictor of sustained virologic response (SVR), spontaneous clearance and personalizing therapy of hepatitis C virus (HCV). This study aimed to determine IL28B rs12979860 polymorphism among chronic hepatitis C (CHC) Egyptian patients as a step in personalized HCV therapy and pharmacogenomics. Methods: CHC Egyptian patients were received sofosbuvir (SOF) plus pegylated interferon (PEG-IFN) and ribavirin (RBV) for 12 weeks. A total of 82 HCV infected Egyptian patients and 27 healthy individuals were included in the present study. CHC Patients were classified as achieving SVR if plasma HCV-RNA was undetectable (group A) and non-responders if plasma HCV-RNA was detectable (group B). IL28B genotypes were analyzed and their associations with SVR were selected. Results: The end of treatment response (ETR) rate was 100%. However,.. View More»
  DOI: 10.4172/2153-0645.1000166

  Abstract PDF